% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Almeida:285007,
author = {L. S. Almeida and E. C. S. d. C. Etchebehere and I. García
Megías and A. K. Calapaquí Terán and B. Hadaschik$^*$ and
P. M. Colletti and K. Herrmann$^*$ and F. Giammarile and R.
C. Delgado Bolton},
title = {{PSMA} {R}adioligand {T}herapy in {P}rostate {C}ancer:
{W}here {A}re {W}e and {W}here {A}re {W}e {H}eading?},
journal = {Clinical nuclear medicine},
volume = {49},
number = {1},
issn = {0363-9762},
address = {[Erscheinungsort nicht ermittelbar]},
publisher = {Ovid},
reportid = {DKFZ-2023-02180},
pages = {45-55},
year = {2024},
note = {2024 Jan 1;49(1):45-55},
abstract = {Diagnosis and treatment of prostate cancer are complex and
very challenging, being a major health care burden. The
efficacy of radioligand therapy with prostate-specific
membrane antigen agents has been proven beneficial in
certain clinical indications. In this review, we describe
management of prostate cancer patients according to current
guidelines, especially focusing on the available clinical
evidence for prostate-specific membrane antigen radioligand
therapy.},
subtyp = {Editorial},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37882758},
doi = {10.1097/RLU.0000000000004919},
url = {https://inrepo02.dkfz.de/record/285007},
}